![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 34, 24279-24292, August 25, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








¶
1
From the
Vascular System Research Center and
Division of Life Sciences, College of Natural Sciences, and ¶Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chunchon, Kangwon-do 200-701, Korea
Received for publication, February 8, 2006 , and in revised form, June 23, 2006.
| ABSTRACT |
|---|
|
|
|---|
3
1 and
6
1 integrins in MelJuSo cells, and activation of associated integrins was a prerequisite for CD151-stimulated MMP-9 expression and activation of FAK, Src, p38 MAPK, JNK, and c-Jun. Furthermore, CD151 on one cell was shown to bind to neighboring cells expressing CD151, suggesting that CD151 is a homophilic interacting protein. The homophilic interactions of CD151 increased motility and MMP-9 expression of CD151-transfected MelJuSo cells, along with FAK-, Src-, p38 MAPK-, and JNK-mediated activation of c-Jun in an adhesion-dependent manner. Furthermore, C8161 melanoma cells with endogenous CD151 were also shown to respond to homophilic CD151 interactions for the induction of adhesion-dependent activation of FAK, Src, and c-Jun. These results suggest that homophilic interactions of CD151 stimulate integrin-dependent signaling to c-Jun through FAK-Src-MAPKs pathways in human melanoma cells, leading to enhanced cell motility and MMP-9 expression. | INTRODUCTION |
|---|
|
|
|---|
The protein CD151 is expressed in various cell types, including epidermal basal cells, epithelial cells, skeletal, smooth and cardiac muscle, endothelial cells, platelets, and Schwann cells (7). Although the physiological function of CD151 is largely unknown, in vitro functional studies showed that CD151 is involved in cell adhesion, motility, and polarity (810). Recently, CD151 was reported to be a positive effector of metastasis, which is contrary to the metastasis-suppressing role of other tetraspanins, such as CD9/MRP-1, CD63/ME-491, and CD82/KAI-1. High CD151 expression was found to be associated with a poor prognosis in lung, colon, and prostate cancer (1113). Monoclonal antibodies to CD151 inhibited in vivo metastasis of human cancer cells and transfection of CD151 cDNA into different tumor cell lines resulted in enhanced cell motility and metastasis (14, 15). This implies that CD151 does not only play an important role in normal physiological processes but also in pathological events, such as tumor cell invasion and metastasis.
CD151 is predominantly localized on the cell surface in contact with basement membranes and to a lesser extent at cell-cell junctions in epithelial cells (7, 16). CD151 forms a multimolecular complex with many other transmembrane proteins. CD151 has been found to form very strong complexes with the
3
1 integrin; moderately stable complexes with
6
1,
6
4, and
7
1 integrins; and less stable, possibly indirect complexes with other integrins, E-cadherin, and other tetraspanins (4, 6, 8, 1619). Since cellular processes regulated by CD151 (such as cell adhesion, migration, and spreading) are integrin-mediated adhesive events, it has been proposed that CD151 modulates integrin activity and function. It was recently demonstrated that CD151 association increases the binding activity of integrin
3
1 to laminin through stabilizing its activated conformation (20). It was also reported that CD151 regulates platelet function by modulating outside-in signaling events of the major platelet integrin
IIb
3 (21). In addition to integrin association, CD151 associates with phosphatidylinositol 4-kinase and protein kinase C on the cytosolic surface, thereby linking integrins to these signaling molecules (8, 22). CD151 has also been shown to regulate expression of a protein-tyrosine phosphatase, PTPµ, and its recruitment to cell-cell junctions (19) and to inhibit adhesion-dependent activation of Ras (23). It thus appears that the intracellular signaling pathways initiated by integrin binding to the extracellular matrix could be altered by the integrin-associated tetraspanin CD151. Taken together, CD151 is thought to participate in adhesion-dependent transmembrane signaling pathways by modulating integrin activity and modifying integrin-mediated outside-in signaling pathways as well. However, the modified integrin signaling pathways by which CD151 manifests its activity have not been established.
In this report, we investigated the functional effects of CD151 expression on cellular activities related to cancer invasion and metastasis and then attempted to identify CD151-mediated signaling pathways for the induction of such cellular functions. We showed that CD151 increases motility and MMP2-9 expression of human melanoma cells through adhesion-dependent c-Jun activation-signaling pathways. Furthermore, we established that these signaling pathways are initiated not only by the matrix binding of integrin molecules but also by homophilic interactions between CD151 proteins on the surface of neighboring cells. Finally, detailed analysis of signaling events indicated that the CD151-
3
1/
6
1 integrin complexes increase c-Jun activity through the activation of FAK, Src, p38 MAPK, and JNK.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Transfection of CD151 cDNA and Selection of Stable ClonesFull-length CD151 cDNA was subcloned into the EcoRI/KpnI sites of a pcDNA3 vector (Invitrogen), downstream of a cyto-megalovirus promoter. The CD151 cDNA expression construct was transfected into MelJuSo human melanoma cells by using Lipofectamine (Invitrogen) according to the manufacturer's instructions. pcDNA3 vector only was also transfected as a control. Neomycin-resistant clones were isolated by growing the cells in DMEM/F-12 containing 10% fetal bovine serum and 0.5 mg/ml G418 (Invitrogen). Stable transfectant clones were characterized by immunoblotting and flow cytometric analyses for their expression levels of CD151 protein.
Transfection of Small Interfering RNA (siRNA)siRNAs for FAK, src, p38 MAPK, and JNK were designed and synthesized using the software and SilencerTM siRNA construction kit from Ambion (Austin, TX) according to the manufacturer's instructions. Specific oligonucleotide sequences for each target gene were as follows: 5'-GAGAAGGCUCAGCAAGAAGdTdT-3' (sense) and 5'-CUUCUUGCUGAGCCUUCUCdTdT-3' (antisense) targeting FAK; 5'-GUGCAUUAAGAACGACGCCdTdT-3' (sense) and 5'-GGCGUCGUUCUUAAUGCACdTdT-3' (antisense) targeting src; 5'-AGCAGGGACCUCCUUAUAGdTdT-3' (sense) and 5'-CUAUAAGGAGGUCCCUGCUdTdT-3' (antisense) targeting p38 MAPK; 5'-UGUCUGGUAUGAUCCUUCUdTdT-3' (sense) and 5'-AGAAGGAUCAUACCAGACAdTdT-3' (antisense) targeting JNK; 5'-CAUCACCUAUUGGAUCCAAdTdT-3' (sense) and 5'-UUGGAUCCAAUAGGUGAUGdTdT-3' (antisense) targeting MMP-9. The siRNA control was 5'-UUCUCCGAACGUGUCACGUdTdT-3' (sense) and 5'-ACGUGACACGUUCGGAGAAdTdT-3' (antisense), which bears no homology with relevant human genes (26). For siRNA transfection, cells (5 x 105) were seeded in 6-well plates and grown for 24 h to reach 6070% confluence. The different amounts of siRNA and the Lipofectamine reagent (5 µl) were diluted in 200 µl of DMEM/F-12 medium. The diluted siRNA-liposome complex was added to cells in DMEM/F-12 medium (800 µl). Following a 6-h incubation, cells were rinsed with fresh medium and grown for 24 h in normal growth medium containing fetal bovine serum before analysis.
Reverse Transcription-PCR AnalysisTotal cellular RNA was purified from the cultured cells using Trizol reagent (Invitrogen) according to the manufacturer's protocol. First strand cDNA synthesis was performed with 1 µg of total RNA using a cDNA synthesis kit (Promega, Madison, WI). For PCR amplification, 5'-aaggtaccaggatgggtgagttcaacgag-3' was used as the sense primer, and 5'-atgaattcggtcagtagtgctccagcttg-3' was used as the antisense primer. This primer pair amplifies a 760-bp fragment of CD151 cDNA. The reaction mixture was subjected to 25 PCR amplification cycles of 60 s at 94 °C, 90 s at 55 °C, and 90 s at 72 °C.
-Actin amplification was used as an internal PCR control (27) with 5'-gatatcgccgcgctcgtcgtcgac-3' as the sense primer and 5'-caggaaggaaggctggaagagtgc-3' as the antisense primer. The PCR products were visualized using ethidium bromide in 1% agarose gel.
Immunoblotting AnalysisCells were washed, harvested, and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 20 µg/ml leupeptin, and 2 mM benzimidine) on ice for 10 min. For phosphoprotein analysis, cell lysis buffer was supplemented with phosphatase inhibitors (1 mM sodium orthovanadate, 1 mM NaF, and 10 mM
-glycerophosphate). After centrifugation at 15,000 x g for 10 min, the supernatants were collected and quantified for protein concentration by Bradford assay. Equal amounts of protein per lane were separated onto 10% SDS-polyacrylamide gel and transferred to an Immobilon-P (Millipore Corp., Bedford, MA) membrane. The membrane was blocked in 5% skim milk for 2 h and then incubated with a specific antibody for 2 h. After washing, the membrane was incubated with a secondary antibody conjugated with horseradish peroxidase. After final washes, the membrane was developed using enhanced chemiluminescence reagents (Amersham Biosciences).
Flow Cytometric AnalysisCells were incubated with 10 µg/ml anti-CD151 monoclonal antibody (mAb) for 30 min, washed with cold PBS, and then incubated with saturating concentrations of fluorescein isothiocyanate-conjugated goat anti-mouse IgG (PharMingen) for 30 min at 4 °C. After washing with PBS, the cells were fixed with 2% formaldehyde in PBS. Cell surface immunofluorescence was analyzed by flow cytometry performed on a FACScan (BD Biosciences).
ImmunoprecipitationCells were lysed in immunoprecipitation buffer (25 mM Hepes, pH 7.5, 150 mM NaCl, 5 mM MgCl2) supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 20 µg/ml leupeptin, and 1% Brij 98 or 1% Triton X-100 for 2 h at 4°C. The lysate was centrifuged (16,000 x g, 15 min), and the supernatant was precleared with a combination of protein A- and protein G-agarose (Amersham Biosciences) precoated with normal mouse IgG for 2 h at 4 °C. After preclearing, the lysate was incubated with a specific antibody coupled to the protein A/G-agarose beads for 2 h at 4 °C. Immune complexes collected on the beads were then washed four times with immunoprecipitation buffer and resolved by SDS-PAGE. Proteins were detected by immunoblotting analysis using specific antibodies.
Invasion Assay into Matrigel24-well Transwell chamber inserts (Corning Costar, Cambridge, MA) with 8-µm porosity polycarbonate filters were precoated with 80 µg of basement membrane Matrigel (BD Biosciences) onto the upper surface and with 20 µg of gelatin onto the lower surface. Culture supernatant of NIH3T3 fibroblasts in DMEM supplemented with 10% fetal bovine serum was placed in the lower well. MelJuSo cells suspended in DMEM/F-12 medium containing 0.1% fetal bovine serum were added to the upper chambers (2 x 104 cells/well) and incubated for 24 h at 37 °C in 5% CO2. Cells were fixed and stained with hematoxylin and eosin. Noninvading cells on the upper surface of the filter were removed by wiping out with a cotton swab, and the filter was excised and mounted on a microscope slide. Invasiveness was quantified by counting cells on the lower surface of the filter.
Wound-healing Migration AssayFor the measurement of cell migration during wound healing, cells (5 x 105) were seeded in individual wells of a 24-well culture plate. When the cells reached a confluent state, cell layers were wounded with a plastic micropipette tip having a large orifice. The medium and debris were aspirated away and replaced by 2 ml of fresh serum-free medium. Cells were photographed every 12 h after wounding by phase-contrast microscopy. For evaluation of "wound closure," five randomly selected points along each wound were marked, and the horizontal distance of migrating cells from the initial wound was measured.
Gelatin ZymographyType IV collagenase activities present in conditioned medium were visualized by electrophoresis on gelatin-containing polyacrylamide gel as previously described (28). Briefly, conditioned medium from cells cultured in serum-free medium was mixed 3:1 with substrate gel sample buffer (40% (v/v) glycerol, 0.25 M Tris-HCl, pH 6.8, and 0.1% bromphenol blue) and loaded without boiling onto 10% SDS-polyacrylamide gel containing type 1 gelatin (1.5 mg/ml). After electrophoresis at 4 °C, the gel was soaked in 2.5% Triton X-100 with gentle shaking for 30 min with one change of detergent solution. The gel was rinsed and incubated for 24 h at 37 °C in substrate buffer (50 mM Tris-HCl, pH 7.5, 5 mM CaCl2, and 0.02% NaN3). Following incubation, the gel was stained with 0.05% Coomassie Brilliant Blue G-250 and destained in 10% acetic acid and 20% methanol.
Cell Aggregation AssayL cells transfected with CD151 or vector alone were washed with PBS containing 2 mM EDTA and rendered into single cell suspension by seven gentle passes through a 22-gauge needle after scraping. After washing with Puck's saline (5 mM KCl, 140 mM NaCl, 8 mM NaHCO3, pH 7.4), suspensions of single cells (1 x 105 cells/ml) were seeded into individual wells of a 24-well culture plate and incubated in 5% CO2 at 37 °C with agitation at 7080 rpm using an orbital shaker. Photographs were taken every 15 min after incubation under a phase-contrast microscope on three predetermined fields, and both the total cell number (A) and the number of cells remaining as single cells (B) were counted. The results were expressed as the percentage of cells that formed aggregates as follows: (A B)/A x 100 (%). In some experiments, the transfectants were preincubated with antibody (20 µg/ml) and then washed free of unbound antibody before incubation. In experiments to determine whether aggregation was homophilic, distinct populations of cells were prelabeled with 5- and 6-CFSE (carboxyfluorescein diacetate succinimidyl ester) (Molecular Probes, Inc., Eugene, OR) before suspension. For these experiments, phase and fluorescent images of the same field were photographed after a 30-min incubation with orbital shaking.
Promoter AssayA 1305-bp DNA fragment (1285 to +20), corresponding to the promoter of the human MMP-9 gene (29, 30), was generously provided by Dr. Seung-Taek Lee (Yonsei University, Korea) (31). For mt-AP-1 of the MMP-9 gene promoter, in which distal and proximal AP-1 binding sites (533 to 527 and 79 to 73, respectively) were destroyed, 5'-TGAGTCA-3' was changed to 5'-TGAGTtg-3' (underlined lowercase letters indicate the mutated bases) by the QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA). For mt-NF-
B of the MMP-9 promoter, in which a NF-
B binding site (600 to 590) was destroyed, 5'-GGAATTCCCC-3' was mutated to 5'-GatcgatCCC-3'. After subcloning the mutant MMP-9 promoters into a promoterless luciferase expression vector, pGL3 (Promega), the corresponding mutations in the constructs were verified by DNA sequencing. The pGL3 vector containing wild-type or mutant MMP-9 promoter was transfected into MelJuSo cells by using Lipofectamine. Luciferase activity in cell lysate was measured using the Promega luciferase assay system according to the instructions of the manufacturer. To normalize luciferase activity, each of the pGL3 vectors was co-transfected with a pRLSV40
Enh, which expresses Renilla luciferase by an enhancerless SV40 promoter (31).
|
B site (607 to 582; 5'-GCCCCGTGGAATTCCCCCAAATCCTG-3'; the NF-
B recognition sequence is underlined) in the proximal MMP-9 promoter sequences were labeled with [
-32P]ATP using T4 polynucleotide kinase and purified by a G-50 Sephadex column. The 32P-labeled probes (
40,000 cpm) were then incubated with nuclear extracts (10 µg of protein) for 20 min at room temperature. Samples were resolved on native 5% polyacrylamide gel, and the gel was dried and subjected to autoradiography. Specificity for binding of AP-1 factors and NF-
B to the corresponding sequences of the MMP-9 promoter was confirmed by using cold competitors having typical AP-1 and NF-
B binding sequences (Promega), respectively. Detergent-free Purification of Membrane FractionsMock and CD151 transfectant cells were washed with ice-cold PBS and then scraped into buffer A (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 20 µg/ml leupeptin, and 2 mM benzimidine). The cells were homogenized using a Dounce homogenizer (20 strokes). A postnuclear supernatant was obtained by centrifugation (2500 x g, 10 min, 4 °C), adjusted to 10% sucrose and loaded onto a 30% sucrose cushion in an ultracentrifuge tube. After centrifugation for 60 min at 150,000 x g in a T-1270 rotor of a tabletop ultracentrifuge (Beckman Instruments), a light-scattering band confined to the 1030% sucrose interface was collected and stored at 70 °C until use.
In Vitro Kinase AssaysCellular proteins (200 µg) were incubated with anti-FAK, anti-Src, or anti-paxillin Abs and immunoprecipitated using protein A/G-agarose beads. Immune complexes collected on the beads were washed three times with immunoprecipitation buffer and once with kinase buffer (20 mM PIPES, pH 7.2, 10 mM MgCl2, 1 mM dithiothreitol) and added to an in vitro kinase reaction mixture containing 5 µg of acid-denatured enolase and 10 µCi of [
-32P]ATP (33). The reaction was incubated at 30 °C for 30 min and then stopped by boiling with SDS-sample buffer. After electrophoresis on a 10% polyacrylamide gel, the radioactive proteins were visualized by autoradiography.
| RESULTS |
|---|
|
|
|---|
|
Induction of MMP-9 Expression by CD151 Is Mediated by Activation of AP-1 FactorsSince MMP-9 appeared to be a target gene up-regulated by CD151 signaling pathway(s) in MelJuSo melanoma cells, we investigated the transcriptional regulation mode of the MMP-9 gene by using several mutants of its 5'-proximal promoter region. When a reporter vector containing a wild-type promoter of the MMP-9 gene was transiently transfected into MelJuSo cells, the CD151 transfectant cells showed about a 20-fold higher luciferase activity than the mock transfectant cells (Fig. 4A). In contrast to the wild-type promoter, the promoters having mutations at the AP-1 binding sites (mt-5'-AP-1 and mt-3'-AP-1) did not respond to CD151 for their activities for reporter gene expression. However, mutation of the NF-
B binding site did not abolish the stimulating effect of CD151 on MMP-9 promoter activity. To determine whether CD151 expression increases DNA binding activity of AP-1 transcriptional factors, we compared the binding of nuclear proteins to a putative AP-1 binding site (79 to 73) of the MMP-9 promoter between mock and CD151 transfectant cells. As shown in Fig. 4B, DNA binding activity of AP-1 factors in CD151 transfectant cells was more significant than that in mock transfectant cells. Moreover, incubation with anti-c-Jun antibody resulted in a partial supershift of the AP-1/DNA complex with the gel shift assay, indicating that c-Jun participates in the formation of the AP-1/DNA complex. Thus, these data indicate that CD151 increases MMP-9 gene transcription by activating AP-1 transcription factors, including c-Jun.
|
3
1 and
6
1 IntegrinsCD151 has been reported to associate with various types of integrins and, in particular, forms stable complexes with
3
1 and
6
1 integrins in many types of cells (4, 6, 8, 17, 18). To determine whether
3
1 and
6
1 integrins are also associated with CD151 in MelJuSo melanoma cells, the CD151-transfected MelJuSo cells were lysed with the nonionic detergent Brij 98, a mild lysis condition preserving tetraspanin-integrin interactions, and the cell lysates were immunoprecipitated with anti-CD151 antibody. As a result,
3,
6, and
1 integrin subunits were detected in the CD151 immunoprecipitate of CD151 transfectant cells but not in mock transfectant cells (Fig. 5A), although the protein level of each integrin subunit was not different between CD151 and mock transfectant cells (Fig. 5B). This result indicates that CD151 can form complexes with
3
1 and
6
1 integrins in MelJuSo cells. Since
3
1 and
6
1 integrins are known to be receptors of laminin/fibronectin and laminin, respectively, we examined whether CD151-stimulated MMP-9 expression is dependent on cell adhesion to extracellular matrix components, such as laminin and fibronectin. As illustrated in Fig. 5C, the stimulating effect of CD151 on MMP-9 expression became more prominent when the cells were attached to laminin, fibronectin, and laminin-rich Matrigel. However, CD151 did not exert its inducing activity for MMP-9 expression when the cells were plated on poly-(L)-lysine, which does not activate integrins. In CD151-deficient mock transfectant cells, a slight increase in MMP-9 expression was observed by cell adhesion to laminin and fibronectin, suggesting that integrin activation alone is not sufficient to induce MMP-9 expression. Thus, CD151 appears to cooperate with associated integrins to induce MMP-9 expression in melanoma cells. To examine how associated integrins activated by their binding to extracellular matrix modulate CD151-dependent signaling pathway(s), the activation status of the CD151 signaling mediators, which were demonstrated in Fig. 3, were compared between mock and CD151 transfectant cells a short time after plating the cells on laminin. CD151 expression significantly elevated phosphorylation-dependent activation of signaling components, such as FAK, Src, p38 MAPK, and JNK dependently of cell adhesion to laminin (Fig. 5D). CD151-mediated phosphorylation of MAPKAPK-2 and c-Jun, downstream effectors of p38 MAPK and JNK, respectively, was also found to be dependent on cell adhesion to laminin. However, adhesion events without integrin activation, such as cell binding to poly-(L)-lysine, did not increase the phosphorylation levels of these CD151 signaling components. On the other hand, phosphorylation of ERK1/2 appeared to be affected by neither integrin activation nor CD151 expression, implying that ERK1/2 does not participate in integrin-dependent CD151 signaling pathways in MelJuSo cells. Taken together, these data strongly suggest that CD151 cooperates with associated integrins to provoke outside-in signaling pathways leading to the activation of FAK, Src, p38 MAPK, JNK, MAPKAPK-2, and c-Jun.
CD151 Is a Homophilic Interacting ProteinSince some membrane proteins involved in cell adhesion and migration, such as E-cadherin and CD99, were found to be self-ligand molecules and their homophilic interactions regulate intracellular signaling pathways (37, 38), we tested the possibility that CD151 is a homophilic interacting membrane protein. After transfecting a CD151 expression vector into murine L-cell fibroblast cells, which do not exhibit homotypic cell-to-cell adhesion, we compared the ability of stable CD151 transfectant L cells to adhere to each other or to empty vector-transfected control L cells by spontaneous cell aggregation assay using cells in suspension. We found that control L cells did not aggregate, but CD151-transfected L cells aggregated in a time-dependent manner (Fig. 6B). The aggregation of CD151-transfected cells was reduced to half after incubation with anti-CD151 antibody, suggesting that the L cell aggregation is mediated by CD151. To confirm whether this aggregation was homophilic, we mixed CD151-transfected L cells with an equal number of fluorescently labeled control L cells. As a result, no fluorescent cells were present in the aggregates, indicating that CD151-expressing L cells did not bind to control L cells lacking CD151 (Fig. 6C). However, when fluorescently labeled CD151 transfectant cells were mixed with unlabeled control L cells, every cell in the aggregates was labeled (Fig. 6D). These data illustrate that CD151-expressing L cells bind only to the same type of L cells having CD151 but not to L cells lacking CD151. It thus appears that CD151 is a homophilic interacting cell surface protein.
Homophilic CD151 Interactions Enhance Cell Motility and MMP-9 ExpressionTo assess the effect of homophilic CD151 interactions on the motility and MMP-9 expression of MelJuSo cells, we prepared membrane fractions of MelJuSo cells transfected with either a CD151 expression vector or empty vector. As expected, CD151 was present in the membrane fraction of the CD151 transfectant but not in that of the mock transfectant (Fig. 7A). The CD151 transfectant cells treated with membrane fraction containing CD151 exhibited increased cell motility compared with untreated cells (Fig. 7B). The CD151-containing membrane fraction also increased MMP-9 expression in CD151 transfectant cells (Fig. 7C). However, pretreatment of CD151 transfectant cells with anti-CD151 Ab blocked the inducing effect of the CD151 membrane fraction on MMP-9 expression (Fig. 7D). Meanwhile, the CD151-deficient membrane fraction obtained from mock transfectant cells did not affect the motility and MMP-9 expression of CD151 transfectant cells. In addition, mock-transfectant cells lacking CD151 did not respond to the CD151-containing membrane fraction for the induction of cell motility and MMP-9 expression. Thus, these results indicate that homophilic interactions of CD151 increase cell motility and MMP-9 expression in MelJuSo cells.
|
We next investigated the possible influence of integrin activation on signaling pathways provoked by homophilic CD151 interactions. When CD151 transfectant cells were seeded onto plates coated with poly-(L)-lysine, homophilic CD151 interactions resulted in a slight increases in the phosphorylation levels of Src and c-Jun, along with no increase in FAK phosphorylation (Fig. 8B). However, cell adhesion to laminin not only increased the phosphorylation level of FAK but also significantly augmented the positive effect of homophilic CD151 interactions on the phosphorylation of Src and c-Jun. Kinase activities of FAK and Src associated with paxillin in focal adhesion complexes were also found to be increased by homophilic CD151 interactions dependent on cell adhesion to laminin (Fig. 8C). These data indicate a stimulating role of integrins in CD151-mediated signaling pathways. Meanwhile, as illustrated in mock transfectant cells attached to laminin, simple activation of laminin-binding integrins without any homophilic CD151 interaction was not sufficient to induce phosphorylation of these signaling molecules. To assess the involvement of CD151-associated integrins,
3
1 and
6
1, in up-regulating CD151 signaling to c-Jun, we incubated CD151 transfectant cells with anti-
1 integrin antibody before seeding the cells on laminin-coated plates. The anti-
1-integrin antibody effectively suppressed the stimulating effect of homophilic CD151 interactions on c-Jun phosphorylation (Fig. 8D), indicating direct participation of
1-type integrins in modulating CD151 signaling for c-Jun activation. The dependence of CD151 signaling on
1-type integrins was also observed in MMP-9 expression (Fig. 8D). Taken together, these results strongly suggest that activation of the CD151-associated
3
1 and
6
1 integrins amplifies the c-Jun activation signaling pathways initiated by homophilic CD151 interactions. We next investigated the participation of MAPKs in CD151 signaling to c-Jun by using inhibitors specific for ERK, p38 MAPK, and JNK. c-Jun phosphorylation in CD151 transfectant cells was significantly blocked by the p38 MAPK inhibitor, SB203580, and the JNK inhibitor, SP600125, as well as by the Src kinase inhibitor, PP1, but not by the ERK inhibitor, PD98059 (Fig. 8E). Since previous results showed CD151-induced adhesion-dependent activation of Src, p38 MAPK, and JNK, but not ERK (Fig. 5D), it is very likely that Src-mediated activation of p38 MAPK and JNK may play an important role in transducing CD151 signals to c-Jun. We finally examined whether integrin-dependent CD151 signaling events also occur in another melanoma cell line, C8161, which possesses endogenous CD151 (Fig. 1A). Similar to CD151-transfected MelJuSo cells, C8161 cells responded to the CD151-containing membrane fraction for the phosphorylation of FAK, Src, and c-Jun in an adhesion-dependent manner (Fig. 8F). However, the phosphorylation levels of these signaling molecules in C8161 cells were not increased in the absence of homophilic CD151 interaction and integrin activation. These results indicate that homophilic CD151 interactions between two contacting human melanoma cells with endogenous CD151 activate the intracellular signaling pathways in one another with the cooperation of associated integrins.
|
| DISCUSSION |
|---|
|
|
|---|
Tetraspanin proteins have been suggested to be involved in signal transduction by regulating the organization and assembly of signaling complexes in membrane microdomains, referred to as the "tetraspanin web" (5, 6, 43). Among the tetraspanins, CD151 shows strong lateral association with laminin-binding integrins, such as
3
1,
6
1,
6
4, and
7
1 (4, 16, 18). We here also found that, in MelJuSo human melanoma cells, CD151 expressed by gene transfection became associated with
3
1 and
6
1 integrins (Fig. 5A). Additionally, CD151 was reported to interact with phosphatidylinositol 4-kinase and protein kinase C, thereby linking integrins to these signaling molecules (8, 22). Several studies have demonstrated that CD151 modulates integrin-dependent cellular activities, including cell adhesion, migration, spreading, and cell morphology on Matrigel (8, 20, 39, 4446). The broad range of integrin association of CD151 and its involvement in integrin-mediated adhesive events strongly suggests a primary role of CD151 in regulating integrin activity and function. Indeed, CD151 association was found to modulate the ligand-binding activity of
3
1 integrin through stabilizing its activated conformation (20). The strength of
6
1 integrin-mediated adhesion to laminin was also enhanced by CD151 (46). Furthermore, outside-in signaling through
6
1 integrin was markedly influenced by its lateral association with CD151 (45). The short C-terminal cytoplasmic region of CD151 was found to be particularly important for determining the outside-in signaling functions of
6
1 integrin (45). Thus, most studies of CD151 have focused on its role in modulating the activity and function of associated integrin molecules. Therefore, participation of CD151 in signal transduction has been confined to its regulatory activity toward integrin-mediated transmembrane signaling events.
|
1 antibody abolished the positive effect of homophilic CD151 interactions on c-Jun activation even when the cells were bound to laminin, demonstrating a critical role of CD151-associated
3
1 and
6
1 integrins in CD151 signaling (Fig. 8D). The dependence of CD151 signaling on integrin activation was also observed in MMP-9 gene expression (Figs. 5C and 8D). Taken together, it appears that CD151 and the associated integrins stimulate signaling-triggering activities reciprocally, suggesting cross-talk between CD151 and integrin signaling events. Furthermore, CD151-
3
1/
6
1 integrin complex-mediated signaling is not only initiated by integrin-activating cell-to-laminin adhesion but also provoked by homophilic CD151 interactions generating0 cell-to-cell adhesion.
|
|
3
1/
6
1 integrin complexes utilize the FAK-Src-MAPKs pathway to increase melanoma cell motility. Since CD151 increases the extracellular matrix binding activity of associated integrins (20, 46) as well as their signaling activity, it is very likely that CD151 contributes to cell movement by strengthening integrin-mediated cell adhesion to the substratum and by activating the FAK-Src-MAPKs pathway. Thus, the role of CD151 in cell movement includes a signaling aspect as well as a structural aspect. Our present data show that the FAK-Src-MAPKs pathway leading to c-Jun activation also plays an essential role in CD151-induced MMP-9 gene expression. The functional role of MAPKs signaling to AP-1 factors in the regulation of MMP-9 expression has been demonstrated in various cell types (64, 69, 70). Taken together, it appears that CD151-integrin complex activates MAPKs, such as p38 MAPK and JNK, through the FAK-Src signaling pathway in MelJuSo cells.
In summary, we have demonstrated for the first time that homophilic CD151 interactions activate integrin-dependent signaling events that lead to increases in c-Jun-mediated MMP-9 gene expression, cell motility, and invasiveness in MelJuSo human melanoma cells. The signaling pathways initiated by CD151-
3
1/
6
1 integrin complexes increase c-Jun activity through the activation of FAK, Src, p38 MAPK, and JNK. Positive cross-talk between p38 MAPK and JNK pathways also contributes to c-Jun activation by CD151-integrin complexes. These findings may be useful in designing therapeutic interventions that block CD151-induced integrin-dependent AP-1 activation through FAK/Src-mediated activation of p38 MAPK and JNK, resulting in the reduction of MMP-9 expression and cell motility and the consequent blocking of invasion and metastatic spread of malignant melanoma.
| FOOTNOTES |
|---|
1 To whom correspondence should be addressed: Division of Life Sciences, College of Natural Sciences, Kangwon National University, Chunchon, Kangwon-do, 200-701, South Korea. Tel.: 82-33-250-8530; Fax: 82-33-244-3286; E-mail: hslee{at}kangwon.ac.kr.
2 The abbreviations used are: MMP, matrix metalloproteinase; FAK, focal adhesion kinase; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; MAPKAPK-2, MAPK-activated protein kinase 2; Ab, antibody; mAb, monoclonal antibody; siRNA, small interfering RNA; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered protein; PIPES, 1,4-piperazinediethane-sulfonic acid. ![]()
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|